Cancer Cell International

Scope & Guideline

Pioneering Insights in Cancer Cell Biology

Introduction

Delve into the academic richness of Cancer Cell International with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN-
PublisherBMC
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationCANCER CELL INT / Cancer Cell Int.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

Cancer Cell International focuses on the multifaceted aspects of cancer biology, treatment, and the underlying molecular mechanisms driving tumor progression and metastasis. The journal aims to disseminate cutting-edge research that contributes to the understanding of cancer and the development of novel therapeutic strategies.
  1. Molecular Mechanisms of Cancer Progression:
    Research articles often explore the intricate molecular pathways involved in cancer initiation and progression, including signaling pathways like Wnt/β-catenin, PI3K/AKT, and mTOR, which are critical for understanding tumor biology.
  2. Role of Non-coding RNAs:
    The journal frequently publishes studies on the regulatory roles of long non-coding RNAs (lncRNAs) and microRNAs in cancer, highlighting their potential as therapeutic targets and biomarkers for diagnosis and prognosis.
  3. Tumor Microenvironment Interactions:
    Research on the interactions between tumor cells and the tumor microenvironment, including cancer-associated fibroblasts and immune cells, is a significant focus, emphasizing the complexity of tumor biology and the potential for targeted therapies.
  4. Therapeutic Strategies and Drug Resistance:
    Papers often address novel therapeutic approaches, including immunotherapy and targeted therapies, as well as mechanisms of drug resistance, providing insights into improving treatment efficacy.
  5. Clinical Implications and Biomarkers:
    The journal emphasizes translational research that connects laboratory findings with clinical applications, aiming to identify novel biomarkers for cancer diagnosis, prognosis, and treatment response.
Cancer Cell International has seen a notable increase in research themes that reflect current trends in cancer research, particularly those integrating modern technological advancements and innovative therapeutic approaches.
  1. Immunotherapy and Immune Checkpoint Inhibition:
    There is a rising trend in studies focusing on immunotherapy, including immune checkpoint inhibitors and CAR-T cell therapies, indicating a shift towards harnessing the immune system in cancer treatment.
  2. Targeting the Tumor Microenvironment:
    Research articles increasingly explore the role of the tumor microenvironment, highlighting the interactions between cancer cells and surrounding stromal and immune cells, which is critical for understanding tumor behavior and treatment response.
  3. Metabolic Reprogramming in Cancer Cells:
    Emerging research on how cancer cells reprogram their metabolism to support growth and survival is gaining traction, with a focus on metabolic pathways that could serve as therapeutic targets.
  4. Application of Machine Learning and AI in Oncology:
    The integration of machine learning and artificial intelligence in cancer research is on the rise, facilitating personalized medicine approaches and enhancing predictive modeling for treatment responses.
  5. Circular RNAs and Novel Biomarkers:
    There is an increasing focus on circular RNAs as potential biomarkers for cancer diagnosis and prognosis, reflecting a growing interest in non-coding RNA research.

Declining or Waning

While Cancer Cell International continues to evolve, certain themes appear to be receiving less attention in recent publications, indicating a possible shift in research focus or a maturation of certain areas.
  1. Traditional Chemotherapy Approaches:
    There seems to be a declining emphasis on traditional chemotherapy methods as the primary focus shifts towards targeted therapies and immunotherapy, reflecting the broader trends in cancer treatment.
  2. Single-agent Drug Studies:
    Research focusing solely on the efficacy of single-agent drugs is becoming less common, with a growing preference for combination therapies that leverage synergistic effects.
  3. Basic Cancer Biology without Clinical Relevance:
    Studies that do not bridge the gap between basic cancer biology and clinical application are becoming less prevalent, as the journal aims to maintain relevance to clinical oncologists and researchers.

Similar Journals

ONCOLOGY RESEARCH

Empowering Researchers to Transform Oncology
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

CELL CYCLE

Advancing the Frontiers of Cell Biology.
Publisher: TAYLOR & FRANCIS INCISSN: 1538-4101Frequency: 24 issues/year

CELL CYCLE, an esteemed journal published by Taylor & Francis Inc., stands at the forefront of biological research, focusing on the intricate mechanisms of cell proliferation, molecular biology, and developmental biology. With an ISSN of 1538-4101 and an E-ISSN of 1551-4005, this journal has established its influence in the field with a commendable impact factor reflecting its rigorous peer-review process and high-quality publications. Notably, in 2023, it achieved a Q1 ranking in Medicine (miscellaneous) and a Q2 ranking in both Cell Biology and Developmental Biology, marking its vital role in advancing scientific understanding and innovation. Operating within a converged framework from 2002 to 2024, CELL CYCLE caters to a diverse audience of researchers, professionals, and students eager to explore contemporary findings and emerging trends. The journal's objective is to disseminate groundbreaking research that enhances our understanding of cellular mechanisms, fostering collaboration and innovation. Although not an open-access journal, it remains a premier source for those engaged in cell cycle research, and its contributions have significant implications for fields such as healthcare, biotechnology, and genetics.

Journal of Cancer Metastasis and Treatment

Unraveling the complexities of cancer treatment.
Publisher: OAE PUBLISHING INCISSN: 2394-4722Frequency: 1 issue/year

Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.

Molecular Oncology

Fostering Excellence in Molecular Oncology Studies.
Publisher: WILEYISSN: 1574-7891Frequency: 10 issues/year

Molecular Oncology, published by WILEY, is a premier open-access journal that has been at the forefront of cancer research since its inception in 2007. With an impressive impact factor reflective of its outstanding contribution to the field, it holds a prestigious position in the Q1 category across multiple disciplines, including Cancer Research, Genetics, and Molecular Medicine. This journal is essential for researchers and professionals seeking to publish high-quality findings in a rapidly evolving area of study, underscored by its significant Scopus rankings that place it within the top percentiles of Oncology and Molecular Biology. As an open-access journal since 2017, it ensures that vital research is readily available to a global audience, thereby facilitating collaboration and knowledge dissemination among academic and clinical communities. With its commitment to innovative and impactful research, Molecular Oncology continues to be a critical resource for advancing our understanding of cancer biology and treatment.

Molecular Therapy Oncolytics

Unleashing the Potential of Molecular Therapies for Cancer
Publisher: CELL PRESSISSN: 2372-7705Frequency: 1 issue/year

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

Cancer Communications

Advancing the Frontiers of Cancer Research
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Exploring breakthroughs in therapeutic strategies.
Publisher: SPANDIDOS PUBL LTDISSN: 1107-3756Frequency: 12 issues/year

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

Molecular & Cellular Oncology

Exploring the cellular mechanisms of oncogenesis.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Pioneering advancements in biotherapy and radiopharmaceuticals.
Publisher: MARY ANN LIEBERT, INCISSN: 1084-9785Frequency: 10 issues/year

Cancer Biotherapy and Radiopharmaceuticals, an esteemed publication by Mary Ann Liebert, Inc., is a premier journal in the field of oncology that addresses the evolving landscape of cancer treatment through innovative biotherapeutics and radiopharmaceutical interventions. With an ISSN of 1084-9785 and an E-ISSN of 1557-8852, this journal provides a vital platform for researchers, clinicians, and industry experts to share cutting-edge findings and methodologies that shape cancer therapeutic practices. Its impressive impact factor and Scopus ranks highlight its significant contribution to the field, particularly within the categories of Oncology and Radiology, where it consistently secures a position in the upper quartiles. As an open access journal, it enables free dissemination of knowledge, ensuring accessibility for a global audience. By focusing on clinical applications, experimental research, and the latest technological advancements, Cancer Biotherapy and Radiopharmaceuticals serves not only as a repository of knowledge but also as a catalyst for future research and development in cancer therapy, making it an invaluable resource for the academic community and healthcare professionals alike.

NAR Cancer

Fostering collaboration to conquer cancer challenges.
Publisher: OXFORD UNIV PRESSISSN: 2632-8674Frequency: 4 issues/year

NAR Cancer, published by Oxford University Press, is a pioneering open access journal established to advance the rapidly evolving field of cancer research. Since its inception in 2019, this journal has gained substantial recognition, achieving a prestigious Q1 ranking in both Cancer Research and Oncology categories as of 2023. With a focused objective to disseminate high-quality research, reviews, and insights into innovative cancer treatments and diagnostics, NAR Cancer serves as an essential platform for researchers, healthcare professionals, and students alike. The journal is accessible for all since it became open access in 2020, ensuring a global reach and impact. Positioned in the competitive landscape of oncology, with impressive Scopus rankings, it offers a unique opportunity for contributors to share their work with an engaged and interdisciplinary audience. With a commitment to excellence, NAR Cancer is dedicated to driving forward the understanding and management of cancer worldwide.